Resources Contact Us Home
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Image Number 13 for United States Patent #8119616.

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a .beta.-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  Recently Added Patents
Data modulation for groups of memory cells
Stereoscopic display
Family of pain producing substances and methods to produce novel analgesic drugs
Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
Current collector for lead acid battery
Segmentation of a product markup image based on color and color differences
Eye therapy system
  Randomly Featured Patents
Foldable support
Phenylserine derivatives as integrin antagonists
Gold plating bath and method
Power actuated tool for driving fastener
Simple circuit and method for improving current balance accuracy of a power converter system
Method for purifying lactams
Electronic device shell
Method of estimating channel bandwidth from a time domain reflectometer (TDR) measurement using rise time and maximum slope
Control of two-phase thermosyphons
Compact dielectric resonator antenna